Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-05-02 | Amended | $10,552,797 | $7,102,798 | Equity Only | 06b | SEC link |
| 2023-12-26 | New | $3,449,999 | $3,449,999 | Equity Only | 06b | SEC link |
| 2022-01-06 | New | $15,044,707 | $15,044,707 | Equity Only | 06b | SEC link |
| 2020-07-22 | Amended | $3,019,999 | $105,409 | Equity Only | 06b | SEC link |
| 2019-07-15 | New | $2,914,590 | $2,914,590 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Ann De Witt | Director |
| Karoly Nikolich | Director |
| Robert Michael Poole | Director |
| Amy Ripka | Director, Executive |
| John Ripple | Director |
| Rachel Sha | Director |